Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA sends complete response letter for ridaforolimus NDA

June 6, 2012

Preclinical study validates new target for resistant tumors

June 6, 2012

PharmaGap provides update on lead program

June 6, 2012

Dr. Reddy's Laboratories enters worldwide biosimilars collaboration

June 6, 2012

MebioPharm set to launch phase II/III MBP-426 trial

June 6, 2012

Research alliance reached for carfilzomib and oprozomib

June 6, 2012

Novel candidate cancer therapies created at Aurigene Discovery Technologies

June 6, 2012

Clinical studies assess daily and twice-daily dosing of golvatinib

June 6, 2012

New phase I data disclosed on KX2-391 in chemotherapy-naive bone-metastatic CRPC

June 6, 2012

Astellas and Ambit begin phase IIb quizartinib monotherapy study in relapsed/refractory AML

June 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...